Executive Summary: Standard in vivo models often fail to replicate the complex hemodynamics and physiology of human cardiovascular disease. For next-generation therapies targeting the heart, advanced surgical models are necessary to generate clinically relevant data for pharmacology and toxicology assessments. This page details the application of specialized surgical techniques in both rodent and large animal models to evaluate vector biodistribution, transgene expression, and functional outcomes, directly supporting US FDA IND submissions under GxP conditions.

Frequently Asked Questions

Q: Why are advanced surgical models required for IND-enabling toxicology studies of cardiovascular gene therapies?

Advanced surgical models are necessary to achieve clinically relevant vector administration and to assess physiological endpoints that standard models cannot capture. Techniques like direct myocardial injection or catheter-based delivery allow for targeted evaluation of efficacy and potential cardiotoxicity, providing data that is more predictive of human outcomes for an IND submission.

Q: How do you ensure GxP compliance and data integrity with complex in vivo surgical procedures?

All IND-enabling studies are conducted in a GxP-compliant environment with rigorous QA oversight. Surgical procedures follow validated SOPs, and all data, from in-life physiological monitoring to terminal histology, are meticulously documented to ensure a complete, auditable data package for regulatory review.

Q: What is the typical timeline for initiating a study involving a custom cardiovascular animal model?

While each program is unique, we can often initiate studies in specialized NHP or large animal models faster than industry averages. The process begins with a consultative design phase with our study directors to align the model with the therapeutic mechanism and regulatory strategy, aiming to move candidates toward IND within an 18-24 month timeline.

Evaluating next-generation therapies for cardiovascular indications demands in vivo models that accurately reflect human disease states and anatomical structures. A standard intravenous infusion in a healthy animal model provides limited insight into how a vector like an AAV will perform when targeted directly to cardiac tissue or the coronary vasculature.

Our approach is to develop a data-driven preclinical strategy tailored to the asset modality and target indication. This involves the use of advanced surgical models to ensure vector delivery and assessment are directly relevant to the proposed clinical application. These complex procedures are performed within our >100,000 sq ft facility, which includes dedicated surgical suites and recovery areas. [FBL-VID-06]

Translating Vector Performance into Clinical Confidence

The selection of a preclinical model and vector serotype is a foundational decision. The performance of AAV8, for instance, has been well-documented in liver-directed applications that have a systemic impact on cardiovascular health. In a humanized model of familial hypercholesterolemia, an AAV8-mediated therapy demonstrated significant lowering of plasma cholesterol, a key surrogate endpoint for cardiovascular risk reduction (PMID: 22985273).

For indications requiring the correction of structural cardiac defects, large animal models provide an indispensable platform. Research in a feline model of MPS I showed that liver-directed AAV8 gene therapy not only achieved sustained enzyme activity but also led to the complete resolution of aortic valve lesions (PMID: 25267637). This outcome provides strong evidence of clinically meaningful benefits that can inform the design of human trials.

Our capabilities extend to a range of surgical techniques, including:
* Direct myocardial and pericardial injections
* Catheter-guided intracoronary artery infusions
* Surgically induced disease models (e.g., myocardial infarction)
* Implantation of telemetry devices for continuous cardiovascular monitoring

From Surgical Suite to Regulatory Submission

Executing these studies is one part of the process. The other is assembling the data into a coherent narrative for regulatory bodies like the US FDA. Every study is designed with the final IND submission in mind. This is central to the 100% successful IND rate our core scientific team has maintained since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024.

By integrating advanced surgical techniques with comprehensive downstream analysis, including multi-channel histology and non-target tissue biodistribution assays, we provide a complete data package. This work is performed as part of our broader Preclinical | Translational Services, which are designed to de-risk therapeutic programs and accelerate their path to the clinic.

Visualization: Comparing Cardiovascular Delivery Approaches